LTR Pharma Nears Milestone in ED Treatment Study

LTR Pharma Limited (AU:LTP) has released an update.

LTR Pharma Limited has addressed a price query from ASX Compliance, confirming no undisclosed information affecting stock trading and reiterating their progress on the SPONTAN® Nasal Spray study for Erectile Dysfunction, which is nearing a critical milestone with results expected in mid-2024. The company remains confident in its compliance with Listing Rules and awaits study outcomes to potentially revolutionize the ED market and advance regulatory discussions.

For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.